Market Cap 251.44M
Revenue (ttm) 0.00
Net Income (ttm) -39.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 1,206,200
Avg Vol 1,719,612
Day's Range N/A - N/A
Shares Out 51.11M
Stochastic %K 72%
Beta 1.58
Analysts Strong Sell
Price Target $16.33

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washing...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 210 2217
Address:
22722 29th Dr. SE, Suite 100, Bothell, United States
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Oct. 25 at 12:16 AM
$ACHV If you haven't watched the HC Wainwright interview then I recommend. Key points are discussed. Link below… Several key items… Rick notes here that they have no specific concerns about the FDA review stating categorically ”we have had a long time to think about this.” He notes CMC and CMO as being the typical highest risk but that they have take significant steps to mitigate risk to both supply and manufacturing by engaging with companies that have previously been inspected by and passed FDA inspection. He also notes that the manufacturer is producing 6 other FDA approved drugs already. Additionally their strategy is a ”staged rollout”. This, to me, serves two purposes. It targets the 7,000 largest prescribers in America which drives revenue as fast as possible. That in turn maximizes value and attractiveness as well as serving as a marketing angle to attract the other 39,000 prescribers who are smaller and who would follow clinical leaders in the space. https://journey.ct.events/view/a601325b-6a76-4cb4-b7cd-0dbff44acf2d
0 · Reply
Mtango
Mtango Oct. 24 at 7:41 PM
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Oct. 24 at 7:36 PM
$ACHV I'm going to be posting a lot of data, really an end to end analysis of this as I see it under this post. For further sections see the comments to this: 1) Clinical & Regulatory Posture (Smoking + Vaping) Smoking: two positive, biochem‑verified P3s; NDA accepted; long‑exposure safety (≥300 @ 6 mo; ≥100 @ 12 mo) being delivered; PDUFA Jun‑20‑2026. Vaping: positive P2 (same MOA), FDA Breakthrough and National Priority 1–2‑month review voucher once sNDA is filed; plan: start P3 ORCA‑V2 in 2H‑2026, file sNDA on readout, Q1‑2027 approval plausible. 2) Approval Probabilities (Not AI Generic, but based on extensive review of data points, comments, and mitigations to risk in place) Smoking PoA: 93–95% (replicated efficacy + clean safety + NDA accepted + long‑exposure safety in hand). Vaping PoA (today): ~95% overall given (a) same API/CMC as smoking label, (b) positive P2, (c) P3 designed to confirm, (d) 1–2‑month review lane; residual risk is execution/labeling, not CMC.
5 · Reply
apatbeck79
apatbeck79 Oct. 24 at 11:17 AM
$ACHV will have a move like $GNTA soon. It’s coming.
1 · Reply
bobtheknob
bobtheknob Oct. 24 at 4:55 AM
$ACHV Just consolidation around support. We could be range bound for some time or we could break out next week. We shall see.
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Oct. 24 at 3:57 AM
$ACHV Generic timing (Part 1) If cytisinicline is approved for smoking in 2026 and vaping in early 2027, a “generic” will have numerous hurdles to clear before being able to launch. In the U.S. you need FDA approval (ANDA or 505(b)(2)). The fiest roadblock is exclusivity: a first-time approval typically gets 5 years of NCE → routine ANDA filing is blocked until 2031 (a patent-challenge filing is allowed at year 4 ≈ 2030, but still no approval before year 5 unless they win in court). A vaping sNDA can add 3-year exclusivity for that use.
3 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Oct. 24 at 3:10 AM
$ACHV × Sopharma — Supply Deal (Part 1: What the paper says) • Term: 20-year A&R Commercial Supply Agreement dated 7/28/2017 → runs to 7/28/2037. • Exclusivity/requirements: Sopharma is the exclusive cGMP supplier for ACHV’s territory; ACHV agrees to purchase all requirements from Sopharma. • Assignability: Automatic assignment on change of control to a buyer that succeeds to substantially all related assets—no consent needed. Other assignments require consent not unreasonably withheld. • Reg/CMC control: Sopharma must provide all data for FDA/EMA, cooperate with inspections. No process/site/material change without ACHV’s prior written approval. • Quality/recall: Recall authority sits with ACHV (the MAH). • Force majeure/supply interruption: Remedies escalate; prolonged disruption can permit termination.
2 · Reply
Sieppo
Sieppo Oct. 23 at 8:01 PM
$ACHV Looked a bit like some shorts panic covering at close.. No other reason for a rip like that during market close.
1 · Reply
V106GuY
V106GuY Oct. 23 at 7:38 PM
$ACHV feels like we hit bottom.
1 · Reply
Delishington
Delishington Oct. 23 at 5:57 PM
$ACHV be patient for payday
0 · Reply
Latest News on ACHV
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Oct. 25 at 12:16 AM
$ACHV If you haven't watched the HC Wainwright interview then I recommend. Key points are discussed. Link below… Several key items… Rick notes here that they have no specific concerns about the FDA review stating categorically ”we have had a long time to think about this.” He notes CMC and CMO as being the typical highest risk but that they have take significant steps to mitigate risk to both supply and manufacturing by engaging with companies that have previously been inspected by and passed FDA inspection. He also notes that the manufacturer is producing 6 other FDA approved drugs already. Additionally their strategy is a ”staged rollout”. This, to me, serves two purposes. It targets the 7,000 largest prescribers in America which drives revenue as fast as possible. That in turn maximizes value and attractiveness as well as serving as a marketing angle to attract the other 39,000 prescribers who are smaller and who would follow clinical leaders in the space. https://journey.ct.events/view/a601325b-6a76-4cb4-b7cd-0dbff44acf2d
0 · Reply
Mtango
Mtango Oct. 24 at 7:41 PM
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Oct. 24 at 7:36 PM
$ACHV I'm going to be posting a lot of data, really an end to end analysis of this as I see it under this post. For further sections see the comments to this: 1) Clinical & Regulatory Posture (Smoking + Vaping) Smoking: two positive, biochem‑verified P3s; NDA accepted; long‑exposure safety (≥300 @ 6 mo; ≥100 @ 12 mo) being delivered; PDUFA Jun‑20‑2026. Vaping: positive P2 (same MOA), FDA Breakthrough and National Priority 1–2‑month review voucher once sNDA is filed; plan: start P3 ORCA‑V2 in 2H‑2026, file sNDA on readout, Q1‑2027 approval plausible. 2) Approval Probabilities (Not AI Generic, but based on extensive review of data points, comments, and mitigations to risk in place) Smoking PoA: 93–95% (replicated efficacy + clean safety + NDA accepted + long‑exposure safety in hand). Vaping PoA (today): ~95% overall given (a) same API/CMC as smoking label, (b) positive P2, (c) P3 designed to confirm, (d) 1–2‑month review lane; residual risk is execution/labeling, not CMC.
5 · Reply
apatbeck79
apatbeck79 Oct. 24 at 11:17 AM
$ACHV will have a move like $GNTA soon. It’s coming.
1 · Reply
bobtheknob
bobtheknob Oct. 24 at 4:55 AM
$ACHV Just consolidation around support. We could be range bound for some time or we could break out next week. We shall see.
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Oct. 24 at 3:57 AM
$ACHV Generic timing (Part 1) If cytisinicline is approved for smoking in 2026 and vaping in early 2027, a “generic” will have numerous hurdles to clear before being able to launch. In the U.S. you need FDA approval (ANDA or 505(b)(2)). The fiest roadblock is exclusivity: a first-time approval typically gets 5 years of NCE → routine ANDA filing is blocked until 2031 (a patent-challenge filing is allowed at year 4 ≈ 2030, but still no approval before year 5 unless they win in court). A vaping sNDA can add 3-year exclusivity for that use.
3 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Oct. 24 at 3:10 AM
$ACHV × Sopharma — Supply Deal (Part 1: What the paper says) • Term: 20-year A&R Commercial Supply Agreement dated 7/28/2017 → runs to 7/28/2037. • Exclusivity/requirements: Sopharma is the exclusive cGMP supplier for ACHV’s territory; ACHV agrees to purchase all requirements from Sopharma. • Assignability: Automatic assignment on change of control to a buyer that succeeds to substantially all related assets—no consent needed. Other assignments require consent not unreasonably withheld. • Reg/CMC control: Sopharma must provide all data for FDA/EMA, cooperate with inspections. No process/site/material change without ACHV’s prior written approval. • Quality/recall: Recall authority sits with ACHV (the MAH). • Force majeure/supply interruption: Remedies escalate; prolonged disruption can permit termination.
2 · Reply
Sieppo
Sieppo Oct. 23 at 8:01 PM
$ACHV Looked a bit like some shorts panic covering at close.. No other reason for a rip like that during market close.
1 · Reply
V106GuY
V106GuY Oct. 23 at 7:38 PM
$ACHV feels like we hit bottom.
1 · Reply
Delishington
Delishington Oct. 23 at 5:57 PM
$ACHV be patient for payday
0 · Reply
Ehri
Ehri Oct. 23 at 5:49 PM
$ACHV How is it possible that with relatively low risk and the highest reward, the price is still at $5?! Where do you see the main risk?! Is it the risk of unexpectedly high side effects in long-term studies?! But the side effect profile of cytisine (which has long been approved for smoking cessation in Europe and other regions under names like Tabex or Asmoken) is widely known.. Thanks!
2 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Oct. 23 at 3:56 PM
$ACHV From ChatGPT PRO: Why are early stage and pre-launch bios red today (10/23/2025): There is no broad sector‑specific negative—this is macro (oil + rates) driven. Oil spike: Brent +~4–5% today after new U.S. sanctions on Rosneft & Lukoil; futures flipped back to backwardation (tight near‑term supply). Rates up: 10‑yr UST ~3.98% today (+~3 bps). Higher discount rates hit long‑duration cash flows first—SMID biotech gets sold. Tape check: XBI trading lower intraday (range ~106.5–107.9). Many single‑names are down far more than the ETF. Policy overhang: Medicare price‑negotiation cycle is in its October window (manufacturers respond to CMS final offers by Oct 31). That keeps a lid on risk appetite. Bottom line: Oil up + rates up = risk‑off. Biotech’s the highest duration in healthcare—so it takes the hit first.
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Oct. 23 at 2:50 PM
$ACHV Testing yesterday's low. 4.86
2 · Reply
Ehri
Ehri Oct. 23 at 11:19 AM
$ACHV 2/2 "The implied enterprise value (EV) for ACHV in 2027 is estimated at between $706.9 million (base value) and $1.5 billion (high potential)."
0 · Reply
Ehri
Ehri Oct. 23 at 11:09 AM
$ACHV Gemini deep research: 1/2 "​This report provides a thorough analysis to determine the realistic acquisition price per share (PPS) for Achieve Life Sciences, Inc. (ACHV) in 2027. The valuation is based on the assumption that cytisinicline has successfully obtained approval for the treatment of nicotine dependence in traditional smokers and has made significant progress in the indication for e-cigarette/vaping consumers... the valuation is primarily conducted using enterprise value to revenue (EV/revenue) multiples. ​The analysis forecasts a broad valuation range, depending on the speed of market penetration and the capitalization of the vaping segment. In the baseline scenario (focus on smoking cessation, based on analyst consensus), a takeover price per share of $20.77 is determined. In the high-potential scenario (integration of the vaping indication and application of an M&A premium multiple), the range is from $30.56 to $42.22 per share."
3 · Reply
bobtheknob
bobtheknob Oct. 22 at 9:27 PM
$ACHV Strong chart today, waiting for the breakout over $6 to get the real bull run going!
1 · Reply
Sieppo
Sieppo Oct. 22 at 8:17 PM
$ACHV a green inverted hammer followed by a beautiful red reversal hammer, should be good. "The red hammer emerges when selling pressure exhausts itself against strong buying interest. Sellers push prices down during the session, sometimes dramatically, only to watch buyers step in and drive prices back up near the opening level. The result? A red candle that looks bearish but actually demonstrates bullish underlying strength." https://www.chartguys.com/articles/red-hammer-candlestick-bullish-reversal
1 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Oct. 22 at 7:52 PM
$ACHV Can it get more definitive?
1 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Oct. 22 at 7:42 PM
$ACHV Sheesh. Look at that textbook double bottom today. $4.85 and $4.85.
2 · Reply
Sieppo
Sieppo Oct. 22 at 7:11 PM
$ACHV double bottomed as the market is possibly recovering.
1 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Oct. 22 at 6:50 PM
$ACHV Honestly... This is holding up far better today than many many many other much more active stocks. Guage the performance relative to the market vs against a perfect day in a vacuum. If we were following a lot of other more trendy companies this would look way worse than -3% right now. There is a lot happening in the macroeconomic space driving the day that has nothing to do with the trajectory or actual fundamental potential and future of ACHV.
1 · Reply